Last reviewed · How we verify
HGP1909
HGP1909 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.
HGP1909 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | HGP1909 |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
HGP1909 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. The drug also suppresses glucagon secretion and slows gastric emptying, collectively reducing postprandial and fasting blood glucose levels. As a long-acting formulation, it provides sustained receptor activation with less frequent dosing.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Hypoglycemia
Key clinical trials
- A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1903 (PHASE1)
- Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HGP1909 CI brief — competitive landscape report
- HGP1909 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI